Breaking News Instant updates and real-time market news.

GS

Goldman Sachs

$245.58

0.34 (0.14%)

, TGT

Target

$125.23

1.36 (1.10%)

09:07
01/15/20
01/15
09:07
01/15/20
09:07

Fly Intel: Pre-market Movers

HIGHER: Fluent (FLNT), up 38% after raising FY19 revenue guidance... PG&E (PCG), up 5% after Citi analyst Praful Mehta upgraded shares to Buy from Neutral with a price target of $15, up from $11. The company's potential agreement with bondholders is a "big step forward" and the "constructive negotiations" referenced in the bankruptcy court yesterday suggest a deal with bondholders is imminent, said the analyst... Community Health (CYH), up 14% after issuing FY20 revenue and EBITDA guidance... Maxar Technologies (MAXR), up 1% after Credit Suisse analyst Robert Spingarn upgraded the stock to Neutral from Underperform with a price target of $22, up from $5.30. In a research note to investors, Spingarn says he thinks the recently-announced MDA sale significantly de-risks the Maxar story. DOWN AFTER EARNINGS: PNC Financial (PNC), down 1%... Goldman Sachs (GS), down 1% ALSO LOWER: Target (TGT), down 7% after reporting holiday period sales and backing its Q4 EPS outlook... Nektar (NKTR), down 11% after withdrawing its new drug application for oxycodegol and announcing it will make no further investment into the program following a FDA panel vote... First Solar (FSLR), down 4% after Barclays analyst Moses Sutton double downgraded shares to Underweight from Overweight with a $49 price target.

GS

Goldman Sachs

$245.58

0.34 (0.14%)

TGT

Target

$125.23

1.36 (1.10%)

NKTR

Nektar

$27.95

0.55 (2.01%)

FSLR

First Solar

$58.81

1.37 (2.39%)

FLNT

Fluent

$2.19

-0.08 (-3.52%)

PCG

PG&E

$11.93

0.93 (8.45%)

CYH

Community Health

$2.67

0.14 (5.53%)

MAXR

Maxar Technologies

$19.78

0.3 (1.54%)

BLK

BlackRock

$519.34

-3.96 (-0.76%)

PNC

PNC Financial

$159.94

0.51 (0.32%)

  • 15

    Jan

  • 15

    Jan

  • 15

    Jan

  • 15

    Jan

  • 15

    Jan

  • 15

    Jan

  • 29

    Jan

  • 13

    Feb

  • 26

    Feb

GS Goldman Sachs
$245.58

0.34 (0.14%)

01/13/20
JMPS
01/13/20
UPGRADE
Target $290
JMPS
Outperform
Goldman Sachs upgraded to Outperform from Market Perform at JMP Securities
JMP Securities analyst Devin Ryan upgraded Goldman Sachs to Outperform from Market Perform with a $290 price target.
01/13/20
JMPS
01/13/20
DOWNGRADE
JMPS
Market Perform
Morgan Stanley, KKR, Apollo cut to Market Perform at JMP Securities
JMP Securities analyst Devin Ryan downgraded Morgan Stanley (MS), KKR (KKR), and Apollo Global (APO) to Market Perform from Outperform while upgrading Goldman Sachs (GS) to Outperform from Market Perform with a price target of $290 as part of a broader research note on investment banks and brokers. The analyst states that the investment tone heading into 2020 is "quite a bit better" than entering 2019, but also sees the bar as having been set higher and macro obstacles, including the presidential elections, as more prevalent. Ryan notes that his reset expectations reflect more company-specific changes or for dislocated valuation, since the current market "base scenario" in the sector is a positive one.
01/13/20
01/13/20
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nvidia (NVDA) upgraded to Hold from Underperform at Needham with analyst Rajvindra Gill citing his "positive" meeting with the company's management at CES. 2. Goldman Sachs (GS) upgraded to Outperform from Market Perform at JMP Securities. 3. 3D Systems (DDD) upgraded to Buy from Hold at Craig-Hallum with analyst Greg Palm saying he believes the narrative is changing at 3D Systems. With a focus on shareholder value, coupled with a return to revenue growth and a major uptick in profitability, Palm thinks shares should start to work higher. 4. New Relic (NEWR) upgraded to Buy from Neutral at UBS with analyst Jennifer Swanson saying the combination of "solid" product and an attractive total addressable market, estimates implying little improvement in execution, and valuation "30% below where it should be" based on peers creates an attractive opportunity with significant potential for shares to re-rate higher. 5. Ericsson (ERIC) upgraded to Buy from Neutral at Citi with analyst Amit Harchandani saying he has a more optimistic view on the pace of 5G adoption and increased his forecast for the radio access network market. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/10/20
PIPR
01/10/20
NO CHANGE
Target $275
PIPR
Overweight
Goldman Sachs price target raised to $275 from $255 at Piper Sandler
Piper Sandler analyst Jeffery Harte raised his price target for Goldman Sachs to $275 from $255 and keeps an Overweight rating on the shares. The analyst cites Goldman's relative business mix heading into 2020 and potential near-term catalysts from its first ever investor day and looming 1MBD settlements for the share price raise.
TGT Target
$125.23

1.36 (1.10%)

01/10/20
CLVD
01/10/20
NO CHANGE
CLVD
Target Q4 'appeared to finish strong,' says Cleveland Research
Cleveland Research analyst Scott Bender said he continues to see upside to consensus comp expectations for Target as his checks indicate that the company seemed to outperform channel expectations and gain share in key holiday categories. The analyst, whose unchanged comp growth and EPS estimates for Target are both above consensus, has a Neutral rating on the shares.
01/08/20
GDHS
01/08/20
NO CHANGE
GDHS
Gordon Haskett shakes up 'Shades of Grey' portfolio with downgrades, upgrade
Gordon Haskett analysts Chuck Grom, John Parke, and Garrett Greenblatt have updated the firm's 'Shades of Grey' portfolio by downgrading four stocks -- Dollar Tree (DLTR) to Reduce from Accumulate, Five Below (FIVE) to Accumulate from Buy, BJ's (BJ) to Hold from Buy, and Tractor Supply (TSCO) to Accumulate from Buy -- and upgrading one stock -- Nordstrom (JWN) to Accumulate from Hold. They also called Dollar General (DG), Target (TGT), and Walmart (WMT) their top ideas. The analysts said the recalibrations were made "very cautiously" and receommended leaning into the new year slowly until more data is released and we have a better grasp on the Q4 and holiday results, 2020 guidance, and overall positioning. The analysts added that they are "sticking to [their] playbook, which is rooted in identifying companies in good retail verticals with strong company-specific comp/GPM drivers to support profitable market share gains."
12/12/19
CLVD
12/12/19
NO CHANGE
CLVD
Neutral
Target Q4 comps tracking ahead of guidance, says Cleveland Research
Cleveland Research analyst Scott Bender's research indicates Target's comps in Q4 are on pace to exceed both the company's guidance and consensus estimates. Holiday sales to date are trending well despite the Thanksgiving timing shift, and most in the channel expect a strong final two weeks before Christmas, Bender tells investors in a research note. The analyst, despite seeing upside to Q4 earnings estimates, keeps a Neutral rating on Target shares.
12/10/19
JEFF
12/10/19
NO CHANGE
Target $2180
JEFF
Buy
Amazon one-day offerings outperformed Target, Walmart in test, says Jefferies
Jefferies analyst Brent Thill said he sampled delivery times during Thanksgiving weekend across popular gifts and grocery products in five key metro areas for Amazon (AMZN), Target (TGT) and Walmart (WMT) and found that Amazon offered one/same-day delivery in meaningfully more markets than either of the brick-and-mortar rivals. Target and Walmart also provided same or next-day shipping on significantly fewer popular gift items, said Thill, who concluded that "one-day delivery isn't created equal." The analyst, who thinks Amazon's superior one-day delivery offering widens its competitive moat, particularly during this year's shortened holiday season, keeps a Buy rating and $2,180 price target on Amazon shares.
NKTR Nektar
$27.95

0.55 (2.01%)

01/10/20
MZHO
01/10/20
NO CHANGE
Target $21
MZHO
Neutral
Nektar briefing docs more negative than positive, says Mizuho
Mizuho analyst Difei Yang views the FDA's briefing documents today on NKTR-181 ahead of the anticipated January 14 panel meeting as "more negative than positive." The FDA notes that "NKTR-181 demonstrates an oral abuse potential comparable to oxycodone following oral administration," the analyst points out. Yang, however, does not expect NKTR-181 or the outcome of the panel meeting to have a meaningful impact on Nektar shares. The value of Nektar will continue to be driven by clinical development of NKTR-214, the analyst tells investors in a research note. She reiterates a Neutral rating on Nektar with a $21 price target. The stock is up 12% to $24.16 in morning trading.
01/10/20
PIPR
01/10/20
NO CHANGE
PIPR
Overweight
Nektar update with Bristol-Myers 'positive all around,' says Piper Sandler
Piper Sandler analyst Tyler Van Buren said news of the amended collaboration between Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) was "a positive update all around" as he believes the new registrational trials in adjuvant melanoma and muscle-invasive bladder cancer essentially expand the commercial opportunity for what are two of the more promising datasets and Bristol's "reset" in first-line lung cancer "is a neutral announcement as no one provided credit for lung anyway" to Nektar. Van Buren, who also contends that "the refined development plan in RCC makes a ton of sense," keeps an Overweight rating on Nektar shares.
01/10/20
GSCO
01/10/20
NO CHANGE
GSCO
Goldman keeps Sell on Nektar despite amended Bristol-Myers Squibb agreement
Goldman Sachs analyst Paul Choi kept a Sell rating and $17 price target on Nektar Therapeutics (NKTR) following the company's amended collaboration agreement with Bristol-Myers Squibb (BMY), which he said provides visibility on the path forward for bempegaldesleukin + Opdivo. While the analyst expects Nektar to trade up following the news, he added that "in the absence of data we do not expect significant credit to be attributed to these additional indications in the near term."
01/10/20
HCWC
01/10/20
NO CHANGE
HCWC
Amended Nektar, Bristol pact reflects bempeg limitations, says H.C. Wainwright
No longer nine malignancies spread across 20 lines of treatment, the amended collaboration between Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) limits bempeg to basically three tumor types, H.C. Wainwright analyst Debjit Chattopadhyay tells investors in a research note. While these programs are to be jointly funded, Bristol would independently conduct and fund a Phase 1/2 dose optimization and expansion study in first-line non-small-cell lung cancer with bempeg and nivolumab, which is a tacit admission of impeding competition from THOR-707, contends the analyst. He believes that should THOR-707 live up to its expectations, any wins for the bempeg combo "could prove to be ephemeral." Chattopadhyay keeps a Neutral rating on Nektar shares with a $32 price target.
FSLR First Solar
$58.81

1.37 (2.39%)

01/06/20
ROTH
01/06/20
NO CHANGE
Target $75
ROTH
Buy
First Solar class action settlement of $350M a win, says Roth Capital
First Solar's payment of $350M to settle the class action lawsuit is a large sum, but a fraction of its potential exposure given the company's $20B market-cap decline during the period outlined in the suit, Roth Capital analyst Philip Shen tells investors in a research note. The analyst views today's news as a positive, saying it largely puts the situation behind First Solar. The $350M settlement is a win for First Solar, contends Shen, who keeps a Buy rating on the shares with a $75 price target. The analyst adds that the settlement removes the inherent risks and uncertainties involved in taking a case all the way to a 10-person jury trial.
12/11/19
JPMS
12/11/19
NO CHANGE
JPMS
JPMorgan still constructive on Alternative Energy, lays out top 2020 picks
JPMorgan analyst Paul Coster remains constructive regarding Alternative Energy fundamentals heading into 2020. He looks for "at-trend" ~$300 billion of investment in 2020 to fund over 200GWs of wind and solar installations, up 10% year-over-year, globally. Adoption is being spurred by falling cost/watt of wind, solar and storage driven by scale and innovation, Coster tells investors in a research note. The analyst's top picks into 2020 are First Solar, SolarEdge (SEDG) and Sunnova Energy (NOVA). He also has Overweight ratings on Bloom Energy (BE), Enphase Energy (ENPH), Hannon Armstrong (HASI), and TPI Composites (TPIC).
01/15/20
LEHM
01/15/20
DOWNGRADE
Target $49
LEHM
Underweight
First Solar downgraded to Underweight from Overweight at Barclays
Barclays analyst Moses Sutton double downgraded First Solar to Underweight from Overweight with a $49 price target.
01/15/20
LEHM
01/15/20
DOWNGRADE
Target $49
LEHM
Underweight
Barclays double downgrades First Solar with Systems business 'in trouble'
Barclays analyst Moses Sutton double downgraded First Solar (FSLR) to Underweight from Overweight with a price target of $49, down from $66. The stock in premarket trading is down 5% to $55.98. After assessing industry data on 5,000 projects, both operational and in the company's pipeline, the analyst believes First Solar's Systems business "is in trouble." This is not a bear call on U.S. Solar, and First Solar's module business is not at risk, Sutton tells investors in a research note. However, its Systems business has lost 80% of its U.S. market share, with NextEra Energy (NEE), EDF and Invenergy gaining share, says the analyst. Sutton expects First Solar's "rapidly declining share" of the U.S. downstream project market to cause a downward re-rating of the shares.
FLNT Fluent
$2.19

-0.08 (-3.52%)

11/12/19
BRRR
11/12/19
DOWNGRADE
BRRR
Market Perform
Fluent downgraded to Market Perform from Outperform at Barrington
Barrington analyst James Goss downgraded Fluent to Market Perform from Outperform without a price target. The company again lowered its revenue guidance, reducing the midpoint of guidance by $15M, which implies an accelerated decline in revenue trends, Goss tells investors in a post-earnings research note. The analyst sees a lack of visibility as to the timing of the company's turnaround and the specifics of future business plans.
03/14/19
BRRR
03/14/19
NO CHANGE
Target $8
BRRR
Outperform
Fluent price target raised to $8 from $6 at Barrington
Barrington analyst James Goss raised his price target for Fluent to $8 from $6 after the company's Q4 results topped expectations. The analyst sees "continued momentum" for Fluent's "growing business" and keeps an Outperform rating on the shares.
05/09/19
ROTH
05/09/19
UPGRADE
ROTH
Buy
Fluent upgraded to Buy from Neutral at Roth Capital
05/09/19
05/09/19
UPGRADE
Target $8.5

Buy
Fluent upgraded to Buy at Roth Capital
As previously reported, Roth Capital analyst William Gibson upgraded Fluent to Buy from Neutral as cash generation continues and based on a more select group of comparable companies. The analyst also raised his price target on the shares to $8.50 from $5.50.
PCG PG&E
$11.93

0.93 (8.45%)

12/18/19
SBSH
12/18/19
UPGRADE
SBSH
Neutral
PG&E upgraded to Neutral at Citi after 'fatal blow' to bondholder plan
Citi analyst Praful Mehta upgraded PG&E to Neutral from Sell after the company won approval for both its settlements as Judge Montali ruled in favor of both RSAs and didn't reject the anti-competitive clauses. The decision means PG&E's "fatal blow to the bondholder plan is confirmed," according to Mehta, who said the questions will now shift to be primarily about financing and the related CPUC and governor approvals. He believes limited debt capacity will increase dilution and likely limit upside, Mehta added. With the "extreme downside scenario" now eliminated, Mehta set an $11 price target on PG&E shares.
12/23/19
BOFA
12/23/19
NO CHANGE
BOFA
PG&E step closer to bankruptcy exit, says BofA
BofA analyst Julien Damoulin-Smith says the most recent rate case settlement by PG&E brings the company a step closer to addressing the operational issues before the June bankruptcy exit deadline. The analyst still notes that the company will likely require a higher degree of spending than it did before the Chapter 11 to develop its wildfire grid resiliency and support its outsized growth.
01/15/20
SBSH
01/15/20
UPGRADE
SBSH
Buy
PG&E upgraded to Buy from Neutral at Citi
Citi analyst Praful Mehta upgraded PG&E to Buy from Neutral.
01/15/20
SBSH
01/15/20
UPGRADE
Target $15
SBSH
Buy
PG&E upgraded to Buy from Neutral at Citi
Citi analyst Praful Mehta upgraded PG&E to Buy from Neutral with a price target of $15, up from $11. The shares closed Tuesday up 85c to $11.92. The company's potential agreement with bondholders is a "big step forward," Mehta tells investors in a research note. The "constructive negotiations" referenced in the bankruptcy court yesterday suggest a deal with bondholders is imminent, says the analyst. Mehta believes that of even if the shareholders give a concession to bondholders, the strategic value of the deal is "significant." Further, a deal would limit the power of the California governor, he adds.
CYH Community Health
$2.67

0.14 (5.53%)

12/19/19
OPCO
12/19/19
NO CHANGE
OPCO
ACA 'status quo' pushes off overhang on hospital, MCO stocks, says Oppenheimer
Oppenheimer analyst Michael Wiederhorn noted that the Fifth Circuit Court of Appeals upheld the ruling that the Affordable Care Act's individual mandate is unconstitutional, but sent the ACA case back to the lower court to reconsider, which he believes was in line with most opinions of what would happen. The ACA uncertainty overhang is "not going away any time soon," but "neither is the ACA," which pushes off another overhang that has been plaguing ACA-impacted stocks such as Medicaid Managed Care Organizations and hospitals, contends Wiederhorn. Publicly traded companies in the medical insurance space include Anthem (ANTM), CVS Health (CVS), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG). Publicly traded companies in the hospital space include Community Health (CYH), HCA Healthcare (HCA), LifePoint (LPNT), Tenet (THC) and Universal Health (UHS).
11/14/19
RBCM
11/14/19
NO CHANGE
Target $4
RBCM
Sector Perform
Community Health assigned Sector Perform rating at RBC Capital
RBC Capital analyst Frank Morgan assigned a Sector Perform rating to Community Health vs. "Not Assigned" previously, also lowering his price target to $4 from $5. The analyst notes that while the company's operating metrics have improved further in Q3, he remains concerned with its "very high" leverage and maturity profile. Morgan concludes that it is "hard to see much upside" on Community Health, absent a decline in leverage and progress on 2023 maturities.
07/10/19
GSCO
07/10/19
UPGRADE
Target $160
GSCO
Buy
Goldman upgrades HCA Healthcare to Buy, boosts priced target to $160
Goldman Sachs analyst Stephen Tanal upgraded HCA Healthcare (HCA) to Buy from Neutral and raised his price target for the shares to $160 from $147. After deep dive of local market competitive dynamics and market share patterns of hospitals, the analyst has a "greater appreciation for the resiliency" of the economic model of certain acute hospitals, notably HCA. The company, and certain other hospital systems, have sufficient bargaining power at the local level to mitigate the effects of any potential negative policy actions taken by government agencies, Tanal tells investors in a research note. The analyst keeps Sell ratings on both Community Health (CYH) and Universal Health (UHS).
09/03/19
EVER
09/03/19
NO CHANGE
EVER
Evercore says Tenet has highest exposure among hospitals to Dorian's new path
Evercore ISI analyst Michael Newshel estimates that Tenet (THC) has 22% of its beds in coastal counties in Florida, Georgia, South Carolina and North Carolina, where mandatory evacuations have been ordered in certain coastal areas due to the expected path of Hurricane Dorian. HCA Healthcare (HCA) has 15% of its beds in coastal counties in Florida, George and South Carolina, including 8% in counties that have received evacuation orders, while Universal Health (UHS) has one acute hospital, representing 3.6% of its total acute beds, in the affected coastal counties, and 8% of its behavioral beds are in coastal counties, the analyst noted. Newshel said Community Health (CYH), Quorum Health (QHC) and Acadia (ACHC) do not have any coastal exposure in the four states expected to be most impacted by Dorian.
MAXR Maxar Technologies
$19.78

0.3 (1.54%)

12/30/19
RAJA
12/30/19
DOWNGRADE
RAJA
Market Perform
Maxar Technologies downgraded to Market Perform from Outperform at Raymond James
Raymond James analyst Steven Li downgraded Maxar Technologies to Market Perform from Outperform.
01/15/20
FBCO
01/15/20
UPGRADE
Target $22
FBCO
Neutral
Maxar Technologies upgraded to Neutral from Underperform at Credit Suisse
Credit Suisse analyst Robert Spingarn upgraded Maxar Technologies to Neutral from Underperform with a price target of $22, up from $5.30. In a research note to investors, Spingarn says he thinks the recently-announced MDA sale significantly de-risks the Maxar story by meaningfully reducing the likelihood of a liquidity crunch. Once closed, the analyst says that the cash proceeds of ~$760M should reduce the debt load by ~24% and bring leverage down close to 5.24x from around 6.64x. While this will cost the company ~10.7% of its forward EBITDA, Spingarn sees Maxar's future tied primarily to its core services businesses, Digital Globe and Radiant Analytics.
01/08/20
JPMS
01/08/20
NO CHANGE
Target $25
JPMS
Overweight
Maxar Technologies price target raised to $25 from $15 at JPMorgan
JPMorgan analyst Benjamin Arnstein raised his price target for Maxar Technologies to $25 from $15 after the company said it would sell its MDA unit for $765M. The stock chart "may look daunting" with the shares up 150% since September, but it is crucial to recall that the story started from a very low base amid concerns about insolvency, Arnstein tells investors in a research note. Leverage concerns are fading following the recent asset sales, says the analyst, who ecalibrated his model and longer term expectations. As a result, the analyst sees "plenty of upside" for the shares and a "clearer path for executing the upcoming cash flow ramp."
12/19/19
CIBC
12/19/19
UPGRADE
Target $15
CIBC
Neutral
Maxar Technologies upgraded to Neutral from Underperformer at CIBC
CIBC upgraded Maxar Technologies to Neutral from Underperformer with a price target of $15, up from $6.25.
BLK BlackRock
$519.34

-3.96 (-0.76%)

01/09/20
DBAB
01/09/20
NO CHANGE
DBAB
Deutsche Bank initiates 'Buy Catalyst Call' on BlackRock
Deutsche Bank analyst Brian Bedell initiated a "Buy Catalyst Call" on BlackRock, hedged against the S&P 500, as he thinks the stock should outperform the equity market during the Q4 earnings. The analyst expects BlackRock to report a "strong" Q4 earnings report in mid January and thinks investors may rotate into traditional asset manager stocks this earnings season.
01/02/20
WELS
01/02/20
UPGRADE
Target $575
WELS
Overweight
BlackRock upgraded to Overweight from Equal Weight at Wells Fargo
Wells Fargo analyst Christopher Harris upgraded BlackRock to Overweight from Equal Weight with a $575 price target.
01/02/20
WELS
01/02/20
UPGRADE
Target $575
WELS
Overweight
BlackRock upgraded to Overweight from Equal Weight at Wells Fargo
Wells Fargo analyst Christopher Harris upgraded BlackRock to Overweight from Equal Weight with a price target of $575, up from $460, as part of a broader note on asset managers. In a research note to investors, Harris says BlackRock has meaningfully outperformed on organic growth, and he now has greater conviction in its ability to do this consistently. Harris adds that BlackRock has significant scale, breadth and depth of capabilities and its iShares ETF platform likely will continue to take market share.
01/08/20
MSCO
01/08/20
NO CHANGE
MSCO
Morgan Stanley a buyer of BlackRock ahead of earnings, reiterates as top pick
Morgan Stanley analyst Michael Cyprys noted that U.S. Traditional Asset Managers start reporting quarterly results next week, with BlackRock (BLK) reporting on January 15. He is raising his Q4 EPS estimates by 2.2% on average for the group, given that he expects rising equity markets will boost asset under management levels. He would be a buyer of BlackRock shares ahead of its report and reiterated the stock as a top pick for 2020, noting that he projects net inflows of $90B in Q4, topping the consensus forecast for $78B inflows. He would be a seller of Legg Mason (LM) and Franklin Resources (BEN) ahead of their reports as his flow estimates for both are below consensus, Cyprys added.
PNC PNC Financial
$159.94

0.51 (0.32%)

12/09/19
12/09/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. 3M (MMM) downgraded to Neutral from Buy at Citi with analyst Andrew Kaplowitz saying with industrial production having peaked in December 2018, the "industrial cycle" is in the midst of a mild downturn that could stabilize. 2. PNC Financial (PNC) downgraded to Outperform from Top Pick at RBC Capital with analyst Gerard Cassidy saying while the outlook for the stock remains "robust" and he still views the company as one of the top performing U.S. banks, he prefers Truist Financial Corporation as his new Top Pick rated bank stock given the opportunity offered by its recent merger combining BB&T (BBT) and SunTrust (STI). 3. Macy's (M) downgraded to Sell from Neutral at Goldman Sachs with analyst Alexandra Walvis saying while acknowledging the stock's year-to-date underperformance and "already weak sentiment" following the recent deterioration in fundamentals, she sees "significant additional downside" to Macy's retail operations. 4. Chevron (CVX) downgraded to Neutral from Buy at Citi with analyst Alastair Syme saying Chevron has emerged as a "relative safe haven" for energy investors given its balance sheet strength and clear capital allocation; however, the "safe-haven status might now be overplayed." 5. Harvard Bioscience (HBIO) downgraded to Speculative Buy from Buy at Benchmark with analyst Bruce Jackson citing the corporate restructuring that the company is undergoing as part of the new strategic plan introduced in September. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/06/20
WELS
01/06/20
DOWNGRADE
Target $61
WELS
Underweight
U.S. Bancorp downgraded to Underweight at Wells Fargo
As previously reported, Wells Fargo analyst Mike Mayo downgraded U.S. Bancorp (USB) to Underweight from Equal Weight with a $61 price target, given his view that the stock will underperform the banking industry over the next 12 months, consistent with his firm's new rating system. Strategically, U.S. Bancorp frittered away a degree of its competitive advantage by not capitalizing more when its competitors were weaker, he contends. Financially, the analyst believes its premium ROE and efficiency should narrow by another 100bp on top of the 300bp narrowing of the past 5 years. The company's newer moves to expand nationally also come later than peer and with new risks and at a time when they have not shown the benefits of harvesting tech benefits to the level of its larger peers or with the clarity of peers such as PNC (PNC), Mayo adds.
01/09/20
BOFA
01/09/20
UPGRADE
Target $178
BOFA
Buy
PNC Financial's EPS growth should help support premium valuation, says BofA
BofA analyst Erika Najarian upgraded PNC Financial to Buy from Neutral with a price target of $178, up from $144. In a research note to investors, Najarian says she views PNC as the "regional bank version" of JPMorgan (JPM) -- the combination of a fortress balance sheet and above-peer growth prospects, but with excess capital. The analyst says the combination of 5% EPS growth and capital return potential at ~10% of market cap should support premium valuations on both earnings and book and drive further outperformance.
01/09/20
BOFA
01/09/20
UPGRADE
BOFA
Buy
PNC Financial upgraded to Buy from Neutral at BofA
BofA upgraded PNC Financial to Buy from Neutral.

TODAY'S FREE FLY STORIES

CLGX

CoreLogic

$44.99

-0.365 (-0.80%)

17:20
01/22/20
01/22
17:20
01/22/20
17:20
Earnings
Breaking Earnings news story on CoreLogic »

CoreLogic sees Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 09

    Mar

TWNK

Hostess Brands

$13.83

-0.06 (-0.43%)

17:19
01/22/20
01/22
17:19
01/22/20
17:19
Initiation
Hostess Brands initiated  »

Hostess Brands initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

PAYC

Paycom

$303.73

3.96 (1.32%)

, WCG

WellCare

$345.79

5.27 (1.55%)

17:18
01/22/20
01/22
17:18
01/22/20
17:18
Hot Stocks
Paycom to replace WellCare in S&P 500 at open on 1/28 »

Centene (CNC) is…

PAYC

Paycom

$303.73

3.96 (1.32%)

WCG

WellCare

$345.79

5.27 (1.55%)

CNC

Centene

$66.72

1.24 (1.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Feb

  • 13

    Feb

AMRN

Amarin

$20.82

-0.24 (-1.14%)

17:18
01/22/20
01/22
17:18
01/22/20
17:18
Hot Stocks
Amarin says payers response on new Vascepa indication 'very positive' »

In a statement to the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAFD

Washington Federal

$35.35

-0.32 (-0.90%)

17:17
01/22/20
01/22
17:17
01/22/20
17:17
Hot Stocks
Washington Federal increases quarterly cash dividend 5% to 22c per share »

The board of Washington…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 24

    Feb

FBNC

First Bancorp

$37.42

-0.37 (-0.98%)

17:16
01/22/20
01/22
17:16
01/22/20
17:16
Earnings
First Bancorp reports Q4 EPS 71c, consensus 78c »

Net interest income for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THS

TreeHouse

$46.83

-0.085 (-0.18%)

17:12
01/22/20
01/22
17:12
01/22/20
17:12
Initiation
TreeHouse initiated  »

TreeHouse assumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

  • 17

    Feb

LW

Lamb Weston

$91.19

0.01 (0.01%)

17:11
01/22/20
01/22
17:11
01/22/20
17:11
Initiation
Lamb Weston initiated  »

Lamb Weston assumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

RP

RealPage

$57.51

-0.29 (-0.50%)

17:10
01/22/20
01/22
17:10
01/22/20
17:10
Hot Stocks
RealPage to acquire Modern Message, terms not disclosed »

RealPage has agreed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

TER

Teradyne

$73.57

2.04 (2.85%)

17:10
01/22/20
01/22
17:10
01/22/20
17:10
Hot Stocks
Teradyne up 8% after Q4 earnings beat and above-consensus Q1 outlook »

Shares of Teradyne are up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

HAIN

Hain Celestial

$25.48

(0.00%)

17:10
01/22/20
01/22
17:10
01/22/20
17:10
Initiation
Hain Celestial initiated  »

Hain Celestial assumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TER

Teradyne

$73.57

2.04 (2.85%)

17:07
01/22/20
01/22
17:07
01/22/20
17:07
Hot Stocks
Teradyne CEO says Q1 outlook reflects the impact of customer production ramps »

CEO Mark Jagiela states:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

OSBC

Old Second Bancorp

$13.21

0.14 (1.07%)

17:07
01/22/20
01/22
17:07
01/22/20
17:07
Earnings
Breaking Earnings news story on Old Second Bancorp »

Old Second Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

CCNE

CNB Financial

$31.13

-0.2 (-0.64%)

17:06
01/22/20
01/22
17:06
01/22/20
17:06
Earnings
CNB Financial reports Q4 EPS 69c, consensus 69c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TER

Teradyne

$73.57

2.04 (2.85%)

17:06
01/22/20
01/22
17:06
01/22/20
17:06
Hot Stocks
Teradyne raises quarterly dividend to 10c from 9c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TER

Teradyne

$73.57

2.04 (2.85%)

17:05
01/22/20
01/22
17:05
01/22/20
17:05
Hot Stocks
Teradyne board authorizes stock buyback of $1B »

Teradyne board authorized…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TER

Teradyne

$73.57

2.04 (2.85%)

17:04
01/22/20
01/22
17:04
01/22/20
17:04
Earnings
Teradyne sees Q1 EPS 86c-96c, consensus 62c »

Sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TER

Teradyne

$73.57

2.04 (2.85%)

17:03
01/22/20
01/22
17:03
01/22/20
17:03
Earnings
Teradyne reports Q4 adjusted EPS 88c, consensus 79c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

OII

Oceaneering

$14.33

-0.08 (-0.56%)

17:02
01/22/20
01/22
17:02
01/22/20
17:02
Hot Stocks
Oceaneering names Earl Childress to succeed Barrett asd SVP business development »

Oceaneering International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 23

    Mar

LYTS

LSI Industries

$6.47

0.13 (2.05%)

17:01
01/22/20
01/22
17:01
01/22/20
17:01
Hot Stocks
LSI Industries to sell Ohio manufacturing facility for $8M »

LSI Industries announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 26

    Mar

PYPL

PayPal

$115.52

-0.62 (-0.53%)

17:01
01/22/20
01/22
17:01
01/22/20
17:01
Hot Stocks
UnionPay, PayPal enter global partnership agreement »

UnionPay International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 09

    Mar

JAGX

Jaguar Health

$0.82

-0.1295 (-13.60%)

16:57
01/22/20
01/22
16:57
01/22/20
16:57
Syndicate
Breaking Syndicate news story on Jaguar Health »

Jaguar Health files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CUBI

Customers Bancorp

$22.51

0.36 (1.63%)

16:56
01/22/20
01/22
16:56
01/22/20
16:56
Earnings
Customers Bancorp reports Q4 core EPS 76c, consensus 74c »

Reports Q4 NII $77.6M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

AFH

Atlas Financial

$0.59

-0.0392 (-6.22%)

16:55
01/22/20
01/22
16:55
01/22/20
16:55
Hot Stocks
Atlas Financial announces LOI for sale of Gateway Insurance to Buckle »

Atlas Financial Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEN

Lennar

$65.75

0.79 (1.22%)

16:50
01/22/20
01/22
16:50
01/22/20
16:50
Hot Stocks
Lennar CFO Diane Bessette sells almost $370K in company shares »

Lennar CFO Diane Besette…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.